| ICG122 / iCell Gene Therap |
NCT04162340: CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies |
|
|
| Recruiting | 1 | 12 | RoW | CD4 CAR T cells | iCell Gene Therapeutics, iCAR Bio Therapeutics Ltd., Peking University Shenzhen Hospital | T Cell Lymphoma in Relapse, Refractory T-Cell Lymphoma | 10/21 | 10/21 | | |
| Recruiting | 1 | 20 | US | CD4CAR | Huda Salman, iCell Gene Therapeutics | T-cell Lymphoma, T-cell Leukemia | 12/25 | 12/37 | | |
NCT06071624: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. |
|
|
| Recruiting | 1 | 30 | US | CD4CAR | Huda Salman, iCell Gene Therapeutics, The Leukemia and Lymphoma Society | Chronic Myelomonocytic Leukemia | 12/28 | 12/43 | | |
